Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A, Itoh K
Departments of Orthopaedic Surgery and Immunology, Kurume University School of Medicine, Japan.
Int J Oncol. 2000 Jul;17(1):29-32. doi: 10.3892/ijo.17.1.29.
We recently reported a tumor-rejection antigen, SART1259, possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs). This study investigated the expression of SART1259 antigen in osteosarcoma and other skeletal malignant tumors to explore for a potential molecule for use in specific immunotherapy. The SART1259 antigen was detected in the cytosol fraction of 13 of 21 (62%) osteosarcoma cell lines and 3 of 8 (38%) osteosarcoma tissues, and 3 of 10 (30%) malignant fibrous histiocytoma (MFH) tissues. The HLA-A24+ and SART1259+ osteosarcoma cells were recognized by the HLA-A24 restricted and SART1 specific CTLs. These results raise a possibility that the SART1259 would be an appropriate molecule for use in specific immunotherapy of approximately one-third of HLA-A24+ patients with osteosarcoma and MFH.
我们最近报道了一种肿瘤排斥抗原SART1259，它具有能够诱导细胞毒性T淋巴细胞（CTLs）的肿瘤表位。本研究调查了SART1259抗原在骨肉瘤和其他骨骼恶性肿瘤中的表达情况，以探索一种可用于特异性免疫治疗的潜在分子。在21个骨肉瘤细胞系中的13个（62%）以及8个骨肉瘤组织中的3个（38%），还有10个恶性纤维组织细胞瘤（MFH）组织中的3个（30%）的胞浆组分中检测到了SART1259抗原。HLA - A24 + 和SART1259 + 的骨肉瘤细胞可被HLA - A24限制且SART1特异性的CTLs识别。这些结果提示，SART1259有可能成为约三分之一HLA - A24 + 的骨肉瘤和MFH患者特异性免疫治疗的合适分子。
